United Therapeutics Corporation (UTHR) Stock Overview
Explore United Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
United Therapeutics Corporation (UTHR)
Key Financials
Key Financials
Market Cap
23.3B
P/E Ratio
18.81
EPS (TTM)
$27.06
ROE
0.19%
UTHR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of United Therapeutics Corporation (UTHR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 48.36, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $502.90.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 18.81 and a market capitalization of 23.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.